Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

JOURNAL ARTICLE published August 2019 in The Lancet Oncology

Authors: Georgina V Long | Reinhard Dummer | Omid Hamid | Thomas F Gajewski | Christian Caglevic | Stephane Dalle | Ana Arance | Matteo S Carlino | Jean-Jacques Grob | Tae Min Kim | Lev Demidov | Caroline Robert | James Larkin | James R Anderson | Janet Maleski | Mark Jones | Scott J Diede | Tara C Mitchell